Market Cap (In EUR)
1.71 Million
Revenue (In EUR)
300.03 Thousand
Net Income (In EUR)
-3.95 Million
Avg. Volume
53.03 Thousand
- Currency
- EUR
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.307-2.4
- PE
- -
- EPS
- -
- Beta Value
- 0.049
- ISIN
- FR0010844464
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Jean-Claude Maurel M.D., MHB
- Employee Count
- -
- Website
- https://www.medesispharma.com
- Ipo Date
- 2021-02-12
- Details
- Medesis Pharma S.A., a clinical development stage biopharmaceutical company, engages in the development of orally administered molecule drug candidates to address unmet medical needs. Its products include NanoLithium (NP03), a clinical stage development product for the treatment of Alzheimer's disease; NanosiRNA DH for the treatment of Huntington's Disease; NU01 Plutonium and NU02 Cesium decorporation products for nuclear decorporation; a radioprotection drug to treat people irradiated following a civil or military nuclear accident (NP02 NanoManganese); NanosiRNA COVID-19, an antiviral treatment solution for viral diseases; and NanosiRNA Resistant cancers and NanosiRNA Oncolytic virus for the treatment of oncology. The company was founded in 2003 and is based in Montpellier, France.
More Stocks
-
BALD-BFastighets AB Balder (publ)
BALD-B
-
IMUC
-
PSHG
-
HEAL
-
600748
-
2490LC Logistics Inc
2490
-
300080
-
GSL-PBGlobal Ship Lease, Inc.
GSL-PB